Akamis Bio

Abingdon, England, United Kingdom

+44 (0)1235 835328 ★

https://www.akamisbio.com

Company profile

Akamis Bio company profile

Akamis Bio is a clinical-stage oncology company whose mission is to use its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to improve the lives of cancer patients. To accomplish this goal, the company is developing a portfolio of solid tumor-targeted T-SIGn® therapeutics that will allow a patient's immune system to recognize, attack, and clear their cancer.

Business identity

Website: https://www.akamisbio.com
Contact email: [email protected]
Phone number: +44 (0)1235 835328
Operating status: Active
Company type: For Profit
Employee range: 00011-00050 employees
Revenue range: $1K+
Founded: 2010-01-01

LinkedIn X

Headquarters

Headquarters: Abingdon, England, United Kingdom
Postal code: OX14 3YS
Country code: GB
Continent: Europe

Capital profile

Funding and company signals

Funding stage: Early Stage Venture
Funding rounds: 10
Total equity funding: $156.3M
Last funding: Series A / $60M / 2024-12-17
Last equity funding: Series A / $60M
Investors: 13
Lead investors: 5
Founders: 3
Articles: 40

Categories and groups

Biotechnology Health Care Oncology Therapeutics Biotechnology Health Care Science and Engineering

Founders and investors

Founders

Andrew CoatsJohn BeadleKerry Fisher

Lead investors

ARCH Venture PartnersBristol-Myers SquibbImperial InnovationsParker Institute for Cancer ImmunotherapySedgwick Yard

Investors

ARCH Venture PartnersBristol-Myers SquibbInvescoSalicaSR One

People at this company

Preview only. Contact details are available after you sign in.

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Shipment records and coverage can change as the dataset is updated.